Palmitoylethanolamide (PEA) for Stage IV Cancer
Also known as: PEA, Normast, Levagen
PEA may reduce cancer-related pain and inflammation while supporting anti-tumor immune responses through mast cell modulation.
Mechanism of Action
PEA modulates tumor-associated mast cells that promote angiogenesis and immunosuppression. It reduces inflammatory pain through PPARα activation, downregulates NF-κB in the tumor microenvironment, and may enhance immune surveillance by reducing immunosuppressive cytokine production.
General mechanism: Endocannabinoid-like lipid. PPARα agonist, mast cell stabilizer, NF-κB inhibitor, neuroinflammation modulator.
Current Evidence
Clinical evidence for cancer pain reduction. Mast cell modulation in tumor microenvironment demonstrated preclinically. Anti-tumor immune effects emerging.
Clinical Status: Used for cancer-related pain. Anti-tumor effects preclinical.
Safety Profile
Excellent safety. No psychoactive effects. No significant drug interactions. Micronized form improves absorption.
Key Research Questions
- Can PEA mast cell modulation improve the tumor immune microenvironment?
- Does PEA reduce cancer treatment side effects?